Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JadiCell™ for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
NCT07479043Phase 3Not yet recruiting
- Sponsor
- Breathe Biologics
- Start
- Mar 2027
- Primary completion
- Oct 2027
- Modality
- Mesenchymal Stem Cells
01
Overview
A Phase 3 trial of JadiCell in acute respiratory distress syndrome (ARDS), sponsored by Breathe Biologics. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
JadiCell
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT07479043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07479043.